Database

Startups

Main Industry
Biotechnology
Main Product/Service
EG BioMed offers a suite of blood-based cancer detection tests based on cfDNA methylation analysis. By evaluating methylation markers in specific genes associated with cancers — such as breast, colon, and pancreatic cancer — their assays provide early det
Founded Year
2022
Unified Business No.
90190353
Status
Active
Number of Employees
0
Total Paid-in Capital
230,300,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
EG BioMed focuses on leveraging DNA methylation technology to develop non‑invasive blood tests for early cancer detection, prognosis monitoring, and recurrence surveillance. With a precision‑medicine approach, they aim to make cancer screening more accessible and accurate — empowering clinicians with individualized molecular data for better decision‑making.



More ↓

Similar Companies

CrackerBio, Inc.

1. NextAmp™ Analysis System
2. PanelChip®
3. DigiChip™ Digital PCR
4. ThyroSCAN
5. FusionQuest

Marker X CO., LTD.

Marker X provides advanced AI proteomics services that combine artificial intelligence with cutting-edge protein analysis technology to promote early disease detection and biomedical innovation. Their core offerings include AI Proteomics Early Cancer Scre

Bloodscan Life Technology CO., LTD.

Labyrinth microfluidic chip has been applied in various academic and clinical studies to enable downstream applications through its high CTC purity, viability, recovery, and unbiased enrichment.